#United States #San Francisco #Heart Failure #Thryv Therapeutics #S GK1 Inhibitors

Thryv Therapeutics Secures Funding for Heart Failure Study

Thryv Therapeutics, a pivotal player in the biotechnology sector, has recently announced a significant milestone with the successful raising of $30 million in Series B financing. This funding, led by InClin, Inc., a global contract research organization, highlights growing investor confidence in Thryv's innovative approach to addressing heart failure and other serious health conditions.

With the support of existing investors, this recent financing will fund the launch of the ASPIRE-HF study. Designed to explore the efficacy of THRV-1268, a selective SGK1 inhibitor, this clinical trial aims to target heart failure patients suffering from reduced ejection fraction alongside extended QTc intervals. Enrollment for this Phase 2a study is set to begin in early 2027, illustrating Thryv's commitment to advancing therapeutic options for those with significant unmet medical needs.

Overview of ASPIRE-HF Study

The ASPIRE-HF study, or Addressing SGK1-driven Prolonged QT and Impaired Remodeling in Heart Failure, will adopt a double-blind, randomized, placebo-controlled format. Participants will undergo a 24-week treatment trial involving either THRV-1268 or a placebo, with interim evaluations occurring at Week 6. This strategy enables researchers to assess the drug's safety, pharmacokinetics, and overall effectiveness in ameliorating heart failure symptoms.

According to Dr. Amy Sehnert, MD, Chief Medical Officer at Thryv, “ASPIRE-HF represents years of foundational work targeting SGK1 as a viable therapeutic pathway. Empirical evidence and earlier Phase 1 results showing QT interval shortening bolster our clinical program's expansion.” Patients with symptomatic heart failure face compounded health risks, including rapid cardiac deterioration and heightened risk of sudden cardiac death due to prolonged QTc intervals. The funding acquired will assist Thryv in addressing these critical clinical concerns with a multifaceted therapeutic approach.

Long QT Syndrome Developments

In parallel with ASPIRE-HF, Thryv is also making strides with its Wave II Phase 2/3 study concerning Long QT Syndrome. This study recently completed its initial efficacy cohort enrollment, with anticipated data releases expected in early 2027. During a review in the third quarter of 2026, the Independent Data Monitoring Committee endorsed the continuation of the study without modifications, confirming that no severe adverse events have been noted so far. This offers reassurance about the safety of THRV-1268 as researchers expand their investigation to include Long QT Syndrome Type 3 patients, allowing eligible participants aged 15 and older to join.

Importance of Upcoming Presentations

To further share its scientific advancements, Thryv Therapeutics is poised to present groundbreaking data at the American Heart Association Scientific Sessions 2026, scheduled from November 6–9, 2026, in Chicago, Illinois. These presentations will focus on SGK1 inhibition's role in managing cardiometabolic heart failures and explore patient-reported symptom burdens in Long QT Syndrome cases.

Conclusion and Future Path

As Thryv pushes forward, its emphasis remains on developing and refining SGK1 inhibitors for conditions that significantly impair heart function and overall health. With the substantial backing from investors like InClin, and ongoing developments in clinical trials, Thryv Therapeutics demonstrates an unwavering dedication to pioneering solutions for heart-related ailments. For further updates and detailed insights, stakeholders and interested parties can visit their official website at www.thryvtrx.com.